desmopressin acetate · Acerus Pharms · NDA 201656
Noctiva
Earliest generic entry, as listed · earliest of 2 marketed strengths
15 Jun 2030
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 11419914, US 12090190, US 9539302.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11419914 | use U-3431 | 15 Jun 2030 |
| US 12090190 | product, use U-4003 | 15 Jun 2030 |
| US 9539302 | product | 15 Jun 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 201656 · 001 · RLD · discontinued | spray, metered, nasal | 0.00083MG/SPRAY | 15 Jun 2030 |
| 201656 · 002 · RLD · discontinued | spray, metered, nasal | 0.00166MG/SPRAY | 15 Jun 2030 |